Functional characterization of HIC, a P2Y1 agonist, as a p53 stabilizer for prostate cancer cell death induction

Author:

Thu Le Hien Thi12,Murugesan Akshaya123,Candeias Nuno R45,Yli-Harja Olli67,Kandhavelu Meenakshisundaram12ORCID

Affiliation:

1. Molecular Signaling Lab, Faculty of Medicine & Health Technology, Tampere University, Finland

2. BioMeditech & Tays Cancer Center, Tampere University Hospital, PO Box 553, 33101, Tampere, Finland

3. Department of Biotechnology, Lady Doak College, Thallakulam, Madurai, 625002, India

4. Faculty of Engineering & Natural Sciences, Tampere University, 33101, Tampere, Finland

5. LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193, Aveiro, Portugal

6. Computational Systems Biology Group, Faculty of Medicine & Health Technology, Tampere University, PO Box 553, 33101, Tampere, Finland

7. Institute for Systems Biology, 1441N 34th Street, Seattle, WA 98103-8904, USA

Abstract

Background: (1-(2-hydroxy-5-nitrophenyl)(4-hydroxyphenyl)methyl)indoline-4-carbonitrile (HIC), an agonist of the P2Y1 receptor (P2Y1R), induces cell death in prostate cancer cells. However, the molecular mechanism behind the inhibition of HIC in prostate cancer remains elusive. Methods & results: Here, to outline the inhibitory role of HIC on prostate cancer cells, PC-3 and DU145 cell lines were treated with the respective IC50 concentrations, which reduced cell proliferation, adherence properties and spheroid formation. HIC was able to arrest the cell cycle at G1/S phase and also induced apoptosis and DNA damage, validated by gene expression profiling. HIC inhibited the prostate cancer cells’ migration and invasion, revealing its antimetastatic ability. P2Y1R-targeted HIC affects p53, MAPK and NF-κB protein expression, thereby improving the p53 stabilization essential for G1/S arrest and cell death. Conclusion: These findings provide an insight on the potential use of HIC, which remains the mainstay treatment for prostate cancer.

Funder

Tampereen Teknillinen Yliopisto

Publisher

Future Science Ltd

Subject

Drug Discovery,Pharmacology,Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3